AstraZeneca Outlines Branded Generics Strategy at Emerging Markets Event
This article was originally published in The Pink Sheet Daily
Executive Summary
AZ's emerging markets strategy includes selective entry into branded generics
You may also be interested in...
AstraZeneca Prepares For U.S. Statin Market Shake-Up As Lipitor Goes Generic
Pricing pressure on AstraZeneca's Crestor expected from the arrival of generic atorvastatin in the U.S. in the fourth quarter.
AstraZeneca Prepares For U.S. Statin Market Shake-Up As Lipitor Goes Generic
Pricing pressure on AstraZeneca's Crestor expected from the arrival of generic atorvastatin in the U.S. in the fourth quarter.
AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
Having endured one major patent expiry in the past year and facing several others in the near future, AstraZeneca has turned in a number of directions to offset potential losses from big sellers like Pulmicort Respules, Nexium, Seroquel, andArimidex, often with mixed results